Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00326664
Other study ID # NCI-2009-00709
Secondary ID NCI-2009-00709CD
Status Completed
Phase Phase 1
First received May 16, 2006
Last updated March 4, 2016
Start date March 2006
Est. completion date July 2015

Study information

Verified date March 2016
Source National Cancer Institute (NCI)
Contact n/a
Is FDA regulated No
Health authority United States: Food and Drug Administration
Study type Interventional

Clinical Trial Summary

This phase I trial is studying the side effects and best dose of AZD2171 in treating young patients with recurrent, progressive, or refractory primary CNS tumors. AZD2171 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.


Description:

PRIMARY OBJECTIVES:

I. Determine the maximum tolerated dose of AZD2171 in pediatric patients with recurrent, progressive, or refractory primary CNS tumors.

II. Describe the toxicity profile and dose-limiting toxicities of AZD2171 in these patients.

SECONDARY OBJECTIVES:

I. Characterize inter-patient variability in the pharmacokinetics of AZD2171 in these patients.

II. Describe changes in circulating endothelial cells (CECs) and circulating endothelial cell precursors (CEPs) in patients treated with AZD2171 at different dose levels.

III. Correlate changes in CECs, CEPs, plasma, serum, and urine levels of proteins with angiogenesis, including vascular endothelial growth factor (VEGF) and VEGF receptor, in patients treated with AZD2171 at different dose levels.

IV. Correlate changes in CECs, CEPs, and angiogenic modulators with changes in magnetic resonance (MR) perfusion.

V. Obtain preliminary evidence of biologic activity of AZD2171 by evaluating alterations in tissue perfusion, tumor blood flow, and metabolic activity using MR perfusion and diffusion imaging, and positron-emission tomography, and correlating these findings with changes in tumor size by standard MRI.

OUTLINE: This is a dose-escalation, multicenter study. Patients are stratified according to concurrent enzyme-inducing anticonvulsant drugs (yes vs no).

Patients receive oral AZD2171 once daily on days 1-28. Treatment repeats every 28 days for up to 13 courses in the absence of disease progression or unacceptable toxicity.

For each stratum, cohorts of 2-6 patients receive escalating doses of AZD2171 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose at which 25% of patients experience dose-limiting toxicity. Once the MTD is determined, an additional 6 patients per stratum are enrolled and treated at the MTD.

After completion of study, patients are followed at 30 days.


Recruitment information / eligibility

Status Completed
Enrollment 55
Est. completion date July 2015
Est. primary completion date July 2015
Accepts healthy volunteers No
Gender Both
Age group N/A to 21 Years
Eligibility Inclusion Criteria:

- Histologically confirmed primary CNS tumor

- Histologically benign brain tumors (e.g., low-grade glioma) allowed

- Histological requirement waived for intrinsic brain stem or diffuse optic pathway tumors, but must have clinical and/or radiographic evidence of progression

- Recurrent, progressive, or refractory disease

- Absolute neutrophil count >= 1,000/mm^3 (unsupported)

- Platelet count >= 75,000/mm^3 (unsupported)

- Creatinine =< 1.5 times upper limit of normal (ULN) OR glomerular filtration rate >= 70 mL/min

- Bilirubin =< 1.5 times ULN

- ALT =< 2.5 times ULN

- Urine dipstick or urinalysis < 1+ protein

- Albumin >= 3 g/dL

- Karnofsky performance status (PS) 60-100% (> 16 years of age) OR Lansky PS 60-100% (=< 16 years of age)

- Karnofsky/Lansky PS 70-100% for patients at increased risk for compromised LVEF

- Hemoglobin >= 8 g/dL (transfusion support allowed)

- No overt renal, hepatic, cardiac, or pulmonary disease

- Not pregnant or nursing

- Negative pregnancy test

- Fertile patients must use effective contraception

- QTc prolongation =< 500 msec

- No other significant ECG abnormality within the past 14 days

- No clinically significant, unrelated, systemic illness, including serious infections or significant cardiac, pulmonary, hepatic, or other organ dysfunction, that would preclude study participation

- No uncontrolled hypertension

- Defined as systolic and diastolic BP > 95th percentile for age (ages 1-17)

- Defined as BP > 140/90 (ages 18 and older)

- No New York Heart Association class III or IV disease and Karnofsky/Lansky PS < 70

- Class II disease controlled with treatment and increased monitoring is allowed

- Recovered from all prior therapy

- No prior AZD2171

- At least 3 weeks since prior myelosuppressive anticancer chemotherapy (6 weeks for nitrosoureas)

- More than 1 weeks since prior investigational or biologic agents

- If the investigational or biologic agent has a prolonged half-life (> 48 hours), then these patients must be discussed with the study chair prior to registration

- No concurrent drugs or biologics with proarrhythmic potential

- More than 3 months since last fraction of craniospinal radiotherapy or total-body irradiation

- More than 4 weeks since last fraction of focal irradiation to symptomatic metastatic sites

- At least 6 months since prior allogeneic bone marrow transplantation

- At least 3 months since prior autologous bone marrow or stem cell transplantation

- At least 1 week since prior filgrastim (G-CSF), sargramostim (GM-CSF), or epoetin alfa (2 weeks for pegfilgrastim)

- No other concurrent investigational agents

- Concurrent dexamethasone allowed provided patient is on a stable or decreasing dose for = 1 week before study entry

- No concurrent chemotherapy

- No concurrent routine use of G-CSF, GM-CSF, or epoetin alfa

- Able to swallow tablets

- Any neurologic deficits must be stable for >= 1 week

- If the investigational or biologic agent has a prolonged half-life (> 48 hours), then these patients must be discussed with the study chair prior to registration

Exclusion Criteria:

- No known curative therapy available

Study Design

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Astrocytoma
  • Brain Neoplasms
  • Childhood Atypical Teratoid/Rhabdoid Tumor
  • Childhood Central Nervous System Germ Cell Tumor
  • Childhood Cerebral Anaplastic Astrocytoma
  • Childhood Cerebral Astrocytoma
  • Childhood Grade I Meningioma
  • Childhood Grade II Meningioma
  • Childhood Grade III Meningioma
  • Childhood Infratentorial Ependymoma
  • Childhood Oligodendroglioma
  • Childhood Spinal Cord Neoplasm
  • Childhood Supratentorial Ependymoma
  • Ependymoma
  • Glioma
  • Medulloblastoma
  • Meningioma
  • Neoplasms
  • Neuroectodermal Tumors
  • Neuroectodermal Tumors, Primitive
  • Oligodendroglioma
  • Optic Nerve Glioma
  • Recurrent Childhood Brain Neoplasm
  • Recurrent Childhood Brain Stem Glioma
  • Recurrent Childhood Cerebellar Astrocytoma
  • Recurrent Childhood Cerebral Astrocytoma
  • Recurrent Childhood Ependymoma
  • Recurrent Childhood Medulloblastoma
  • Recurrent Childhood Pineoblastoma
  • Recurrent Childhood Subependymal Giant Cell Astrocytoma
  • Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor
  • Recurrent Childhood Visual Pathway Glioma
  • Rhabdoid Tumor
  • Spinal Cord Neoplasms

Intervention

Drug:
Cediranib Maleate
Given orally

Locations

Country Name City State
United States Dana-Farber/Harvard Cancer Center Boston Massachusetts
United States Lurie Children's Hospital-Chicago Chicago Illinois
United States Duke University Medical Center Durham North Carolina
United States Texas Children's Hospital Houston Texas
United States Pediatric Brain Tumor Consortium Memphis Tennessee
United States St. Jude Children's Research Hospital Memphis Tennessee
United States Children's Hospital of Philadelphia Philadelphia Pennsylvania
United States Children's Hospital of Pittsburgh of UPMC Pittsburgh Pennsylvania
United States UCSF Medical Center-Mount Zion San Francisco California
United States Seattle Children's Hospital Seattle Washington
United States Children's National Medical Center Washington District of Columbia

Sponsors (1)

Lead Sponsor Collaborator
National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Maximum tolerated dose, defined as the dose at which the model estimates that 25% of patients will experience dose-limiting toxicity as measured by NCI CTCAE v4.0 Estimated using the modified Continual Reassessment Method (CRM). 42 days Yes
See also
  Status Clinical Trial Phase
Withdrawn NCT02194452 - Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors N/A
Completed NCT00053963 - FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia Phase 1
Active, not recruiting NCT03233204 - Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00091182 - Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment Phase 2
Completed NCT00095940 - Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors Phase 1/Phase 2
Completed NCT00052780 - Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors Phase 1
Completed NCT00004078 - Irinotecan in Treating Children With Refractory Solid Tumors Phase 2
Completed NCT00100880 - Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Phase 1
Recruiting NCT02359565 - Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma Phase 1
Terminated NCT01088763 - Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00101270 - Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas Phase 1
Active, not recruiting NCT03210714 - Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) Phase 2
Completed NCT00363272 - Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma Phase 1
Completed NCT00946335 - ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Phase 1
Completed NCT00063973 - Cilengitide in Treating Children With Refractory Primary Brain Tumors Phase 1
Completed NCT01462695 - Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma Phase 2
Completed NCT03387020 - Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors Phase 1
Active, not recruiting NCT00638898 - Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor Phase 1
Recruiting NCT05857969 - Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
Completed NCT03860376 - Ex Vivo Drug Sensitivity Testing and Mutation Profiling